Neurofibromatosis Type 1 Market: By Drug type, By Disease Type, By Treatment Type, By Distribution Channel, and Geography

Neurofibromatosis Type 1 Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug type (Lamotrigine, Selumetinib, Others), By Disease Type (Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Others), By Treatment Type (Medication, Surgery, Radiation Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region

Neurofibromatosis Type 1 Market size was valued at US$ 8,356.3 million in 2023 and is expected to grow at an 9.3% CAGR from 2024 to 2030. Neurofibromatosis Type 1 is a complex genetic disorder characterized by the development of tumors along nerves in the skin, brain, and other parts of the body. This condition affects approximately 1 in 3,000 to 4,000 individuals worldwide, making it one of the most common inherited neurological disorders. One of the primary drivers is the increasing prevalence of neurofibromatosis type 1. This growing patient population is fueling demand for improved diagnostic tools and treatment options. Advancements in diagnostic techniques have also contributed to neurofibromatosis type 1 market growth. The introduction of next-generation sequencing and other molecular diagnostic methods has enhanced the accuracy and speed of neurofibromatosis type 1 diagnosis.

For instance, a 2023 study reported that advanced genetic testing techniques could identify neurofibromatosis type 1 mutations in over 95% of cases, compared to about 80% with traditional methods. Growing awareness among healthcare professionals and the general public is another crucial factor. Patient advocacy groups and initiatives like the Children's Tumor Foundation's "Shine a Light on NF" campaign have significantly increased visibility and understanding of the condition. This has led to earlier diagnoses and increased research funding for neurofibromatosis type 1. The neurofibromatosis type 1 market presents several opportunities, particularly in the development of targeted therapies and personalized medicine approaches. The approval of selumetinib in 2020 for pediatric neurofibromatosis type 1 patients with symptomatic, inoperable plexiform neurofibromas marked a significant milestone. This has paved the way for increased investment in similar targeted therapies, with over 30 clinical trials for neurofibromatosis type 1 treatment registered as of 2024.

However, the neurofibromatosis type 1 market faces certain restraints, including the complexity of the disease and limited treatment options for all manifestations of neurofibromatosis type 1. The heterogeneity of symptoms and the unpredictable nature of tumor growth pose challenges for developing universally effective treatments. Current trends in the neurofibromatosis type 1 market include a focus on gene therapy research, with several preclinical studies showing promising results. The use of artificial intelligence in diagnosis and treatment planning is also gaining traction. A recent pilot study demonstrated that AI algorithms could detect neurofibromatosis type 1-associated tumors with 92% accuracy, potentially speeding up diagnosis and monitoring. Collaborative efforts between pharmaceutical companies and research institutions have accelerated drug development.

Key Developments:

  • In April 2023, European Commission approved expanded use of AstraZeneca's selumetinib (Koselugo) for neurofibromatosis type 1 patients aged 3 years and older with inoperable plexiform neurofibromas.
  • In September 2023, National Cancer Institute's combination therapy Phase II trial results of trametinib (Novartis) and pexidartinib (Daiichi Sankyo) showed promising outcomes for adult neurofibromatosis type 1 patients with inoperable plexiform neurofibromas.

Neurofibromatosis Type 1 Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.3%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Neurofibromatosis Type 1 Market Dynamics

The Neurofibromatosis Type 1 market is significantly driven by increasing prevalence and advancements in diagnostic techniques. Recent epidemiological studies suggest neurofibromatosis type 1 may affect up to 1 in 2,000 individuals worldwide, higher than previous estimates. This rise in prevalence is partly due to improved detection capabilities and increased awareness among healthcare professionals, leading to more accurate and early diagnoses. The genetic nature of neurofibromatosis type 1, with a 50% inheritance rate, also contributes to its growing prevalence. Simultaneously, diagnostic technologies have undergone remarkable advancements. Next-generation sequencing techniques have improved genetic testing accuracy, now detecting neurofibromatosis type 1 mutations in over 95% of cases compared to 80% with traditional methods. Molecular imaging, particularly whole-body MRI, has enhanced the detection and monitoring of internal neurofibromas. The integration of artificial intelligence in image analysis shows promise in identifying neurofibromatosis type 1-associated tumors with high accuracy, potentially expediting diagnosis and monitoring processes.

Neurofibromatosis Type 1 Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 8,356.3 million

Market CAGR

9.3%

By Drug Type

  • Lamotrigine
  • Selumetinib
  • Others

By Disease type

  • Plexiform Neurofibromas
  • Cutaneous Neurofibromas
  • Optic Gliomas
  • Others

By Treatment

  • Medication
  • Surgery
  • Radiation Therapy
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Key Features of the Report

  • The neurofibromatosis type 1 market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

Frequently Asked Questions

Neurofibromatosis Type 1 Market was valued at US$ 8,356.3 million in 2023 and is expected to grow at an 9.3% CAGR from 2024 to 2030.

AstraZeneca plc, Novartis AG, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Johnson & Johnson, and F. Hoffmann-La Roche Ltd. are some of the major players operating in the neurofibromatosis type 1 market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period.

North America accounts for the largest market share and is expected to be the primary market driver in the neurofibromatosis type 1 market.

Key challenges include the variable expression of the disease, the complexity of the neurofibromatosis type 1 gene, and the need for long-term studies to assess treatment efficacy and safety.

Yes, in 2020, the FDA approved selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Neurofibromatosis Type 1 Market Introduction 
2.1.Global Neurofibromatosis Type 1 Market  - Taxonomy
2.2.Global Neurofibromatosis Type 1 Market  - Definitions
2.2.1. Drug Type
2.2.2.Disease type
2.2.3.Treatment
2.2.4.Distribution Channel
2.2.5.Region
3.Global Neurofibromatosis Type 1 Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Neurofibromatosis Type 1 Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Neurofibromatosis Type 1 Market  By  Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Lamotrigine
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Selumetinib
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Others
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Neurofibromatosis Type 1 Market  By Disease type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Plexiform Neurofibromas
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Cutaneous Neurofibromas
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Optic Gliomas
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Neurofibromatosis Type 1 Market  By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Medication
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Surgery
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Radiation Therapy
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Neurofibromatosis Type 1 Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Neurofibromatosis Type 1 Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Lamotrigine
10.1.2.Selumetinib
10.1.3.Others
10.2.  Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Plexiform Neurofibromas
10.2.2.Cutaneous Neurofibromas
10.2.3.Optic Gliomas
10.2.4.Others
10.3.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Medication
10.3.2.Surgery
10.3.3.Radiation Therapy
10.3.4.Others
10.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1.  Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Lamotrigine
11.1.2.Selumetinib
11.1.3.Others
11.2.  Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Plexiform Neurofibromas
11.2.2.Cutaneous Neurofibromas
11.2.3.Optic Gliomas
11.2.4.Others
11.3.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Medication
11.3.2.Surgery
11.3.3.Radiation Therapy
11.3.4.Others
11.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1.  Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Lamotrigine
12.1.2.Selumetinib
12.1.3.Others
12.2.  Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Plexiform Neurofibromas
12.2.2.Cutaneous Neurofibromas
12.2.3.Optic Gliomas
12.2.4.Others
12.3.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Medication
12.3.2.Surgery
12.3.3.Radiation Therapy
12.3.4.Others
12.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1.  Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Lamotrigine
13.1.2.Selumetinib
13.1.3.Others
13.2.  Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Plexiform Neurofibromas
13.2.2.Cutaneous Neurofibromas
13.2.3.Optic Gliomas
13.2.4.Others
13.3.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Medication
13.3.2.Surgery
13.3.3.Radiation Therapy
13.3.4.Others
13.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1.  Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Lamotrigine
14.1.2.Selumetinib
14.1.3.Others
14.2.  Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Plexiform Neurofibromas
14.2.2.Cutaneous Neurofibromas
14.2.3.Optic Gliomas
14.2.4.Others
14.3.  Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Medication
14.3.2.Surgery
14.3.3.Radiation Therapy
14.3.4.Others
14.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.AstraZeneca plc
15.2.2.Novartis AG
15.2.3.Merck & Co., Inc.
15.2.4.Pfizer Inc.
15.2.5.Sanofi S.A.
15.2.6.Johnson & Johnson
15.2.7.Hoffmann-La Roche Ltd.
15.2.8.Takeda Pharmaceutical Company Limited
15.2.9.Eli Lilly and Company
15.2.10.GlaxoSmithKline plc
15.2.11.Bristol-Myers Squibb Company
15.2.12.Bayer AG
15.2.13.Boehringer Ingelheim International GmbH
15.2.14.Gilead Sciences, Inc.
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • AstraZeneca plc
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Hoffmann-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Gilead Sciences, Inc.

Related Industry Reports